Revvity Inc. (RVTY) To Go Ex-Dividend on October 23rd

Revvity Inc. (NYSE:RVTY) declared a quarterly dividend on Friday, July 31st. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share on Friday, November 13th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd.

Revvity has a dividend payout ratio of 5.1% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Revvity to earn $5.92 per share next year, which means the company should continue to be able to cover its $0.28 annual dividend with an expected future payout ratio of 4.7%.

Revvity Stock Up 0.2%

Shares of RVTY stock traded up $0.25 on Wednesday, hitting $156.26. The stock had a trading volume of 238,786 shares, compared to its average volume of 1,503,452. The firm has a market capitalization of $17.44 billion, a price-to-earnings ratio of 74.52, a P/E/G ratio of 2.75 and a beta of 1.06. The stock’s 50 day moving average is $137.99 and its 200-day moving average is $114.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity has a 52-week low of $81.22 and a 52-week high of $166.25.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts expect that Revvity will post 5.36 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Tajinder Vohra sold 7,330 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the transaction, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 9,045 shares of company stock worth $1,281,439 over the last ninety days. 0.85% of the stock is currently owned by company insiders.

Institutional Trading of Revvity

Institutional investors have recently modified their holdings of the company. Ascentis Independent Advisors bought a new position in Revvity during the first quarter worth about $29,000. Global Retirement Partners LLC bought a new position in Revvity during the second quarter worth $51,000. SJS Investment Consulting Inc. increased its holdings in shares of Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after purchasing an additional 521 shares during the last quarter. Summit Securities Group LLC increased its holdings in shares of Revvity by 294.6% in the first quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock valued at $58,000 after purchasing an additional 495 shares during the last quarter. Finally, Contravisory Investment Management Inc. acquired a new position in shares of Revvity in the first quarter valued at $66,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.